ADELAIDE, AUSTRALIA, March 19, 2024 Carina Biotech to Present Three Poster Presentations at AACR Annual Meeting 2024 Carina Biotech Limited (Carina), a clinical stage cell therapy immuno-oncology company, today announced
ADELAIDE, AUSTRALIA, December 19, 2023 Carina Biotech Doses First Patient in Phase 1/2a Clinical Trial of LGR5-Targeted CAR-T Cell Therapy First patient dosed in Australia where 3 clinical trial sites have
ADELAIDE, AUSTRALIA, September 13, 2023 Carina Biotech (Carina) invited to present at 7th annual Cell and Gene Therapy World Asia 2023 Conference Carina Biotech, a cell therapy immuno-oncology company, will
ADELAIDE, AUSTRALIA, August 21, 2023 Carina Biotech to Present Preclinical Data Evaluating LGR5-Targeted CAR-T Cell Therapy in Human Cancer Models at 8th CAR-TCR Summit LGR5 is expressed, both in vitro
ADELAIDE, AUSTRALIA, June 5, 2023 Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced the appointment of Michael S. Wyzga, M.B.A., and Remus Vezan M.D., Ph.D., to its Board
ADELAIDE, AUSTRALIA, May 25, 2023 Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced that the management team will participate in the three upcoming conferences as follows: 9th Annual Immuno-Oncology Innovation Forum will
ADELAIDE, AUSTRALIA, April 2, 2023 Carina Biotech to Present Details of Planned Phase 1/2a Clinical Trial of LGR5-Targeted CAR-T Cell Therapy Candidate CNA3103 for Metastatic Colorectal Cancer at 2023 ASCO
ADELAIDE, AUSTRALIA, March 22, 2023 Carina Biotech to Present Preclinical Data Evaluating LGR5-Targeted CAR-T Cell Therapy in Colorectal Cancer Models at 2023 AACR Preclinical data demonstrates that LGR5-targeting CAR-T therapy
PRESS RELEASE, February 7, 2023 Carina Biotech to Present Preclinical Data at Lorne Cancer 2023 Supporting Effectiveness of LGR5-Targeted CAR-T Cell Therapy Platform in Ovarian Cancer Tumor Models Preclinical evidence
PRESS RELEASE Tuesday, January 24, 2023 Carina Biotech Receives FDA “Safe to Proceed” Letter for IND Application for Phase 1/2a Clinical Trial of LGR5-Targeted CAR-T Cell Therapy Candidate for Treatment
